AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01244243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand & Wrist Assisting Robotic Device
Description: Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
Study NCT03507374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alirocumab
Description: Alirocumab is approved by the FDA as a secondary treatment for high cholesterol for adults whose cholesterol can not be controlled by diet and/or statin treatment. Additionally, Alirocumab works to inhibit the PCSK9 protein.
Study NCT03507374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
Study NCT01215422 — intervention group
Intervention type: PROCEDURE
Intervention: timed intubation
Description: timed intubation
Study NCT00261768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital noise reduction
Study NCT03330457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus)
Description: fXa inhibitor antidote
Study NCT03330457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 80 mg PO QD
Description: fXa inhibitor
Study NCT03330457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (infusion IV)
Description: fXa inhibitor antidote
Study NCT04183972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound examination
Description: the participants will be placed in the supine position, with head turned slightly away from the operating side and arms beside the body. The operator will identify right and left interscalene brachial plexuses by ultrasound equipment (Sonosite EDGE or GE LOGIQ e). Clear images and videos of brachial plexus will be captured and saved.
Study NCT02715167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide novolizer
Study NCT02715167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00122928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program
Study NCT00122928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees
Study NCT00122928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental Obesity Program - Healthy Culture
Description: Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition
Study NCT03665896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubation with VivaSight double-lumen tube
Study NCT03665896 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: intubation with standard double-lumen tube
Study NCT03665896 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fiberoptic bronchoscopy
Study NCT03665896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronchoscopy
Study NCT02909270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mediclore
Description: to apply mediclore fully around thyroid gland
Study NCT00792805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 µg
Description: Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study NCT00792805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study NCT00792805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study NCT04586517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy-load resistance training
Description: Supervised heavy-load resistance training during chemotherapy treatment
Study NCT04586517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Activity as usual during chemotherapy
Study NCT03096366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
Study NCT03096366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
Study NCT03096366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
Study NCT03450798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOFT block group
Description: needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
Study NCT03450798 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: spinal anesthesia group
Description: patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
Study NCT01727622 — intervention group
Intervention type: DRUG
Intervention: FDG-PET
Description: Diagnostic: FDG-PET imaging to examine neuronal health
Study NCT01727622 — intervention group
Intervention type: OTHER
Intervention: ASL-MRI
Description: Arterial-Spin Labeled MRI to examine cerebral blood flow
Study NCT01727622 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
Study NCT02808143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Solution
Description: Given intravesically
Study NCT02808143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02808143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravesically
Study NCT02808143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02721745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural Fatigue
Description: Experimental: EEG Indirect Calorimetry Pupillometry
Study NCT02721745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Experimental: EEG Indirect Calorimetry Pupillometry
Study NCT02721745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Experimental: EEG Indirect Calorimetry Pupillometry
Study NCT01177787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zeltiq
Description: Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
Study NCT01177787 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: electrical stimulation
Description: Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
Study NCT02598752 — intervention group
Intervention type: OTHER
Intervention: Symptom-limited cardiopulmonary exercise test (CPET)
Study NCT02598752 — intervention group
Intervention type: OTHER
Intervention: Resting assessment of cardiac function by echocardiography
Study NCT02598752 — intervention group
Intervention type: OTHER
Intervention: Post-exercise assessment of cardiac function by echocardiography
Study NCT02598752 — intervention group
Intervention type: OTHER
Intervention: Pulmonary function
Study NCT02598752 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient-reported outcomes questionnaire
Study NCT03265834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: < 10 days of antibiotics
Description: Antibiotic duration
Study NCT03265834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 28 days of antibiotics
Description: Antibiotic duration
Study NCT02711488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.~The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager.
Study NCT02170454 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: magnetic stimulation
Description: rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
Study NCT02170454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic stimulation
Description: rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
Study NCT01410136 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chondrofix Osteochondral Allograft
Description: Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
Study NCT02090374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug
Study NCT02090374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Poly I:C
Description: Single dose: 500ug
Study NCT02090374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R848
Description: High dose: 10ug Low dose: 1-2ug
Study NCT02090374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timothy Grass Pollen
Description: Dose: 5000 SQ-U/100µl
Study NCT02090374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 4000U orally
Study NCT02090374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuberculin
Description: Tuberculin PPD
Study NCT01480674 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Study NCT03404765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Study NCT02689596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT02689596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00309556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 6 cycles 75mg/m2 i.v. day 1 q3w
Study NCT00309556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 6 cycles 75mg/m2 i.v. day 1 q3w
Study NCT00309556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 6 cycles 1000mg/m2 oral, day 1-14 q2d
Study NCT00309556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
Study NCT00786825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatostatin
Description: Somatostatin may be used to suppress endogenous insulin secretion
Study NCT04615247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Program
Description: The yoga program is designed to maximize women's awareness of and control over the pelvic floor, promote relaxation, and improve physical function.
Study NCT04615247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Conditioning Program
Description: The physical conditioning program will focus on a core set of exercises designed to improve physical function and emotional well-being in order to improve management of chronic pain.
Study NCT04577196 — intervention group
Intervention type: OTHER
Intervention: Trauma dashboard
Description: A large dashboard available to all, providing a framework for synthesizing and displaying relevant information about the arriving critical patient, to be filled in by the trauma leader.
Study NCT03400332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: Specified dose on specified days
Study NCT03400332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03400332 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03400332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT03400332 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT03400332 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT01942720 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Capsule endoscopy and Ileocolonoscopy tests
Study NCT02013505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
Study NCT03064386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plate fixation
Description: internal fixation with the plate
Study NCT03064386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screw fixation
Description: internal fixation with the screw
Study NCT02277405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shikani Optical Stylet
Description: Optical intubation
Study NCT02277405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoeye Flexible Intubation (LF-V)
Description: endoscopy intubation
Study NCT03537287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alpha hydroxyprogestrone caproate
Description: 250 mg of 17 alpha hydroxyprogestrone caproate weekly
Study NCT03537287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: 200 mg of vaginal progesterone daily
Study NCT03537287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral dydrogesterone
Description: 2 tablets of dydrogesterone daily
Study NCT03525899 — intervention group
Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy
Description: Pars plana vitrectomy combined with Internal limiting membrane peeling, inverted internal limiting membrane flap insertion into the macular hole, or lens anterior or posterior capsular flap insertion into the macular hole
Study NCT02031289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
Description: Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po.
Study NCT00151957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Transdermal System
Description: MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
Study NCT02842840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-based intervention
Study NCT02842840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family based intervention
Study NCT02842840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine counseling
Study NCT01054651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate+Sulfamethoxypyrazine/pyrimethamine
Study NCT01054651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Study NCT02088749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention for obesity
Study NCT02088749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention for obesity
Study NCT02215538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Study NCT02215538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication appears identical to the active medication OROS methylphenidate
Study NCT02579174 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK Sphere
Study NCT01319214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inderal
Description: Inderal vs. placebo will be administered with or without cocaine cues
Study NCT00683176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choline Fenofibrate
Description: 135 mg
Study NCT00683176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02272855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HF10 plus Ipilimumab
Description: Patients will receive the dose of 1 x 10\^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Study NCT01596907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine sulfate with caffeine
Description: Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
Study NCT01596907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cellulose
Description: sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
Study NCT02361138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Study NCT02361138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00830648 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Virus Vaccine
Description: 0.5 mL, Subcutaneous
Study NCT03289377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RDAD Training
Description: An interactive processes of lecture, role-play, and discussion, APNs will have the opportunity to dissect all phases of RDAD to insure they understand the objectives, can enact the program, and feel confident they can problem-solve situations that arise. APNs will receive materials to insure they are knowledgeable about ADRD symptoms, behavior management techniques, and exercise safety.